New daily adaptive radiotherapy aims to spare saliva glands in head and neck cancer patients

NCT ID NCT07348887

Recruiting now Symptom relief Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether daily adaptive radiotherapy (DART) can better protect the submandibular glands during head and neck cancer treatment compared to standard image-guided radiation. About 50 participants will be randomly assigned to receive either standard or adaptive therapy. The main goal is to see if DART helps maintain saliva production and reduces dry mouth side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daily adaptive radiation therapy (DART)
What this could lead to: If successful, this approach could reduce dry mouth and improve quality of life for head and neck cancer patients undergoing radiation.
What could go wrong: This is a small, early-phase trial with only 50 participants. The technique may not significantly improve saliva production or could have unforeseen side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.